印度最高法院允许Natco出售廉价的通用Risdiplam, 引用Roche专利上的公共卫生理由。 India's Supreme Court lets Natco sell cheap generic Risdiplam, citing public health over Roche's patent.

印度最高法院驳回了Roche的上诉, 允许印度非专利药商Natco Pharma继续出售廉价的脊椎肌肉萎缩药物Risdiplam。 The Supreme Court of India has dismissed Roche’s appeal, allowing Indian generic drugmaker Natco Pharma to continue selling a lower-cost version of the spinal muscular atrophy drug Risdiplam. 法院维持了德里高等法院驳回Roche临时禁令的一项决定,指出公众对以负担得起的方式获得救生药品有利益。 The court upheld a Delhi High Court decision that denied Roche an interim injunction, citing public interest in affordable access to life-saving medication. Roche辩称,其专利权应当受到保护,但法院强调,在紧急卫生案件中,患者的可负担性和获得权大于专利专有权。 Roche had argued its patent rights should be protected, but the courts emphasized that patient affordability and access outweighed patent exclusivity in urgent health cases. 该案现在将开始审判,Natco准备以大大降低的价格推出其通用版本。 The case will now proceed to trial, with Natco set to launch its generic version at a significantly reduced price.